SI-BONE, Inc. (SIBN) stock
SIBNNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/3042% above fair value
$23.16−0.25 (-1.07%)
Close on Nov 17, 2026Market cap $1.04BP/E –Yield 0.00%
Si-Bone r&d expenses
Research and development expenses are spending on new products and technology.
Si-Bone's R&D Expenses for the twelve months ending Jun 30, 2026 was $18.02M, up 7.9% year over year. For fiscal 2025 it was $17.45M, up 5.4% from the year before. The highest annual figure on record is $17.45M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.45M | +5.4% |
| FY2024 | Dec 31, 2024 | $16.56M | +10.2% |
| FY2023 | Dec 31, 2023 | $15.03M | +10.3% |
| FY2022 | Dec 31, 2022 | $13.63M | +9.5% |
| FY2021 | Dec 31, 2021 | $12.44M | +31.5% |
| FY2020 | Dec 31, 2020 | $9.46M | +29.9% |
| FY2019 | Dec 31, 2019 | $7.28M | +35.4% |
| FY2018 | Dec 31, 2018 | $5.38M | -2.5% |
| FY2017 | Dec 31, 2017 | $5.51M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $5.22M | +21.2% |
| Q1 FY2026 | Mar 31, 2026 | $4.19M | -7.5% |
| Q4 FY2025 | Dec 31, 2025 | $4.36M | +12.7% |
| Q3 FY2025 | Sep 30, 2025 | $4.24M | +6.2% |
| Q2 FY2025 | Jun 30, 2025 | $4.31M | -1.0% |
| Q1 FY2025 | Mar 31, 2025 | $4.53M | +4.3% |
| Q4 FY2024 | Dec 31, 2024 | $3.87M | -7.0% |
| Q3 FY2024 | Sep 30, 2024 | $3.99M | +1.9% |
| Q2 FY2024 | Jun 30, 2024 | $4.35M | +19.0% |
| Q1 FY2024 | Mar 31, 2024 | $4.35M | +32.0% |
| Q4 FY2023 | Dec 31, 2023 | $4.16M | +19.6% |
| Q3 FY2023 | Sep 30, 2023 | $3.92M | +26.9% |
| Q2 FY2023 | Jun 30, 2023 | $3.66M | +5.1% |
| Q1 FY2023 | Mar 31, 2023 | $3.29M | -8.1% |
| Q4 FY2022 | Dec 31, 2022 | $3.48M | +14.1% |
| Q3 FY2022 | Sep 30, 2022 | $3.09M | -6.1% |
| Q2 FY2022 | Jun 30, 2022 | $3.48M | +10.4% |
| Q1 FY2022 | Mar 31, 2022 | $3.58M | +21.2% |
| Q4 FY2021 | Dec 31, 2021 | $3.05M | +25.7% |
| Q3 FY2021 | Sep 30, 2021 | $3.29M | +18.4% |
| Q2 FY2021 | Jun 30, 2021 | $3.15M | +45.5% |
| Q1 FY2021 | Mar 31, 2021 | $2.96M | +41.4% |
| Q4 FY2020 | Dec 31, 2020 | $2.43M | +36.6% |
| Q3 FY2020 | Sep 30, 2020 | $2.78M | +48.2% |
| Q2 FY2020 | Jun 30, 2020 | $2.17M | +11.3% |
| Q1 FY2020 | Mar 31, 2020 | $2.09M | +24.2% |
| Q4 FY2019 | Dec 31, 2019 | $1.78M | +18.3% |
| Q3 FY2019 | Sep 30, 2019 | $1.87M | +36.5% |
| Q2 FY2019 | Jun 30, 2019 | $1.95M | +50.2% |
| Q1 FY2019 | Mar 31, 2019 | $1.68M | +39.6% |
| Q4 FY2018 | Dec 31, 2018 | $1.50M | +17.4% |
| Q3 FY2018 | Sep 30, 2018 | $1.37M | -6.3% |
| Q2 FY2018 | Jun 30, 2018 | $1.30M | – |
| Q1 FY2018 | Mar 31, 2018 | $1.21M | – |
| Q4 FY2017 | Dec 31, 2017 | $1.28M | – |
| Q3 FY2017 | Sep 30, 2017 | $1.47M | – |
See a number that looks wrong?